Is BMRN a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases (BMRN) rests on Voxzogo growth engine: Voxzogo, for children with achondroplasia, generated roughly $920 million in 2025 and remains the primary growth driver, with most sales coming from outside the United States. Revenue (2025) is ~$3.2B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. Whether BMRN is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases, a niche where it has decades of experience. Its commercial base includes enzyme replacement therapies (Vimizim, Naglazyme, Palynziq and others) for lysosomal and metabolic disorders, plus Voxzogo, an injectable for children with achondroplasia that has become the company's fastest-growing product. In April 2026 BioMarin closed its roughly $4.8 billion all-cash acquisition of Amicus Therapeutics, adding Galafold for Fabry disease and the Pombiliti plus Opfolda regimen for Pompe disease to the portfolio. Separately, the company decided to withdraw its Roctavian hemophilia gene therapy from the market after failing to find a buyer, taking an asset write-down. The investment picture is one of steady, high-margin growth from a diversified set of rare-disease franchises rather than a single blockbuster bet. BioMarin generated about $3.2 billion of revenue in 2025 and has guided 2026 revenue to roughly $3.83 to $3.93 billion, an acceleration driven largely by the Amicus products and continued Voxzogo uptake. The bull case is durable pricing power, orphan-drug exclusivity, and Voxzogo label expansion; the bear case is heavy reliance on a few products, integration risk from the Amicus deal, and a valuation that already prices in growth.
What's the case for buying BMRN?
1. Voxzogo growth engine
Voxzogo, for children with achondroplasia, generated roughly $920 million in 2025 and remains the primary growth driver, with most sales coming from outside the United States. BioMarin is pursuing label expansions and additional indications that could widen the addressable population. Continued patient additions are central to the company's raised 2026 outlook.
2. Amicus acquisition and portfolio breadth
The roughly $4.8 billion Amicus deal, completed in April 2026, added Galafold for Fabry disease and Pombiliti plus Opfolda for Pompe disease. Management expects the deal to be slightly dilutive to 2026 non-GAAP earnings but accretive starting in 2027. Successful integration diversifies revenue beyond the legacy enzyme therapies and Voxzogo.
3. Enzyme therapy base and margins
Established enzyme replacement products such as Vimizim, Naglazyme and Palynziq provide a stable, high-margin cash-generating base with long orphan-drug exclusivity. This recurring revenue funds research and the pipeline. Double-digit growth across enzyme therapies contributed to record 2025 revenue.
4. Pipeline optionality
BioMarin is advancing internal programs including BMN 333, BMN 351 and BMN 401, alongside further Voxzogo indications. These earlier-stage assets offer longer-term upside if trials read out well. The company has also shown willingness to prune assets, as with the Roctavian withdrawal, to focus resources.
What are the risks to BMRN?
Revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. Rare-disease pricing draws scrutiny from payers and governments, and much of Voxzogo's revenue comes from international markets subject to reimbursement pressure. Competition is emerging, including Ascendis Pharma's TransCon CNP in achondroplasia and multiple Fabry and Pompe therapies from larger rivals. The Amicus acquisition adds integration and execution risk, and the Roctavian withdrawal shows that expensive programs can fail commercially. The shares trade at a premium multiple, leaving little margin for disappointment.
How is BMRN valued? (as of JULY 2026)
Snapshot for BMRN as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (2025): ~$3.2B
- 2026 revenue guidance: ~$3.83B to $3.93B
- Q1 2026 revenue: ~$766M
- Q1 2026 non-GAAP EPS: ~$0.76
- 2026 non-GAAP EPS guidance: ~$4.85 to $5.05
- Market cap: ~$11B
BioMarin posted record 2025 revenue of about $3.2 billion and raised its 2026 revenue guidance to roughly $3.83 to $3.93 billion after adding the Amicus products, implying around 20 percent growth at the midpoint. Non-GAAP EPS guidance for 2026 was trimmed slightly to about $4.85 to $5.05 to reflect near-term dilution from the acquisition. Reported trailing GAAP multiples look elevated versus biotech peers, so the story depends on the guided growth materializing.
How do you decide if BMRN is a buy?
Rather than asking whether BMRN is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold BMRN indirectly through an index or sector ETF before adding more.
For the full picture, see the BMRN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about BMRN against your real portfolio and see your actual exposure before deciding.
The bottom line on BMRN
The bottom line: BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases's story right now is Voxzogo growth engine, with revenue (2025) at ~$3.2B. If you believe that narrative continues, the call is about sizing BMRN sensibly and checking overlap with what you own; if you doubt it (the risk: revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around BMRN with Walnut
Use BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is BMRN a good stock to buy right now?
+
The case for BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases right now is Voxzogo growth engine, with revenue (2025) at ~$3.2B. If you believe that thesis holds, BMRN is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases do?
+
BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases, a niche where it has decades of experience.
What are the main risks of BMRN?
+
Revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. Rare-disease pricing draws scrutiny from payers and governments, and much of Voxzogo's revenue comes from international markets subject to reimbursement pressure. Competition is emerging, including Ascendis Pharma's TransCon CNP in achondroplasia and multiple Fabry and Pompe therapies from larger rivals. The Amicus acquisition adds integration and execution risk, and the Roctavian withdrawal shows that expensive programs can fail commercially. The shares trade at a premium multiple, leaving little margin for disappointment.
What does BioMarin do?
+
BioMarin develops and commercializes therapies for rare genetic diseases. Its portfolio includes enzyme replacement therapies for lysosomal and metabolic disorders, Voxzogo for children with achondroplasia, and, following the 2026 Amicus acquisition, Galafold for Fabry disease and the Pombiliti plus Opfolda regimen for Pompe disease.
How do you invest in BMRN?
+
BMRN trades on the Nasdaq, so you can buy shares through any brokerage account, either as a standalone position or as part of a healthcare or rare-disease themed basket. Some investors also gain exposure indirectly through biotech and healthcare ETFs that hold the stock.
Is BMRN a good investment?
+
That depends on your goals, time horizon and risk tolerance, and Walnut is not an investment adviser. The descriptive picture is a profitable rare-disease specialist with accelerating revenue but concentrated product risk and a premium valuation, so it is worth weighing the growth drivers against the risks yourself or with a licensed adviser.
What is BioMarin's biggest growth driver?
+
Voxzogo, its treatment for children with achondroplasia, is the fastest-growing product, generating roughly $920 million in 2025. Continued patient additions and potential label expansions make it central to the company's raised 2026 outlook, alongside the newly acquired Amicus products.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell BMRN; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.